Menu

EMAP
Estudis en Medicaments en Atenció Primària (EMAP)

Group leader
avatar_investigadors.jpg
Rosa Morros Pedrós
rmorros@idiapjgol.org
avatar_grups_recerca.png

Projects

Group projects

Servei Farmacovigilancia estudi: Exploratory, Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Safety and Impact on HIV-1 Reservoir of Baricitinib in Virologically Suppressed People With HIV-1

  • Principal investigators: Silvia Fernández García, Rosa Morros Pedrós
  • Code: 9F-0-00023-25
  • Start year: 2025

Plasma Exchange Therapy for Post- COVID-19 Condition: A Pilot, Randomized Double-Blind Study – PAX

  • Principal investigators: Silvia Fernández García, Rosa Morros Pedrós
  • Code: 9F22/006
  • Start year: 2022
  • Funders: Fundació Lluita contra la Sida. Hº Trias i Pujol

A Non-Interventional Multi-Country Post-Authorisation Safety Study (PASS) to Assess the Incidence of Serious Infections & Malignancies in Systemic Lupus Erythematosus (SLE) Patients Exposed to Anifrolumab

  • Principal investigators: Rosa Morros Pedrós, Maria Giner Soriano
  • Code: 4RNC-0-00379-25
  • Start year: 2026
  • Funders: AstraZeneca Farmacéutica Spain, S.A.

TARGET EU – Comparative effectiveness and safety studies using the target trial emulation and estimand frameworks: Rivaroxaban and risk of major gastrointestinal bleeding in elderly patients with non-valvular atrial fibrillation (version 0.3, 10 November 2025)

  • Principal investigators: Maria Giner Soriano
  • Code: 4RNC-0-00338-25
  • Start year: 2025

Servei de Farmacoviligancia de l’assaig: A single-center, self-controlled, prospective case series pilot study to assess the effect of lamivudine (3TC) on neurocognitive impairment biomarkers and type-I IFN (interferon)-stimulated genes in the plasma of patients with Mild Cognitive Impairment (MCI)

  • Principal investigators: Rosa Morros Pedrós
  • Code: 9F-0-00052-24
  • Start year:

Board of Trustees

Collaborators

Accreditations